These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 11783773)

  • 21. Vitreous penetration of orally administered valacyclovir.
    Huynh TH; Johnson MW; Comer GM; Fish DN
    Am J Ophthalmol; 2008 Apr; 145(4):682-6. PubMed ID: 18226802
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Valacyclovir for herpes simplex encephalitis.
    Pouplin T; Pouplin JN; Van Toi P; Lindegardh N; Rogier van Doorn H; Hien TT; Farrar J; Török ME; Chau TT
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3624-6. PubMed ID: 21576427
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Carrier-mediated intestinal absorption of valacyclovir, the L-valyl ester prodrug of acyclovir: 1. Interactions with peptides, organic anions and organic cations in rats.
    Sinko PJ; Balimane PV
    Biopharm Drug Dispos; 1998 May; 19(4):209-17. PubMed ID: 9604120
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of valaciclovir.
    MacDougall C; Guglielmo BJ
    J Antimicrob Chemother; 2004 Jun; 53(6):899-901. PubMed ID: 15140857
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aciclovir and its l-valyl ester, valaciclovir.
    Smiley ML; Murray A
    Curr Probl Dermatol; 1996; 24():209-18. PubMed ID: 8743272
    [No Abstract]   [Full Text] [Related]  

  • 26. Use of therapeutic drug monitoring in the long-term valaciclovir therapy of relapsing herpes simplex virus encephalitis in children.
    Lim M; Menson E; Tong CY; Lin JP
    J Antimicrob Chemother; 2009 Dec; 64(6):1340-1. PubMed ID: 19828489
    [No Abstract]   [Full Text] [Related]  

  • 27. A new paediatric formulation of valaciclovir: development and bioequivalence assessment.
    Bastiaans DE; Bartels-Wilmer CM; Colbers AP; Heijens CA; Velthoven-Graafland K; Smeets OS; Vink N; Harbers VE; Warris A; Burger DM
    Arch Dis Child; 2016 Oct; 101(10):971-2. PubMed ID: 27162003
    [No Abstract]   [Full Text] [Related]  

  • 28. A novel nucleoside prodrug-activating enzyme: substrate specificity of biphenyl hydrolase-like protein.
    Kim I; Song X; Vig BS; Mittal S; Shin HC; Lorenzi PJ; Amidon GL
    Mol Pharm; 2004; 1(2):117-27. PubMed ID: 15832508
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Valaciclovir (BW256U87): the L-valyl ester of acyclovir.
    Jacobson MA
    J Med Virol; 1993; Suppl 1():150-3. PubMed ID: 8245883
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bioequivalence studies of two different film-coated tablet formulations of valacyclovir of two different strengths in healthy volunteers.
    Neves R; Almeida S; Filipe A; Spinola AC; Abolfathi Z; Lévesque A; Ortuño J; Torns A
    Arzneimittelforschung; 2010; 60(5):273-81. PubMed ID: 20533765
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acyclovir levels in serum and cerebrospinal fluid after oral administration of valacyclovir.
    Lycke J; Malmeström C; Ståhle L
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2438-41. PubMed ID: 12878501
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Peptide transporter family].
    Terada T; Inui K
    Tanpakushitsu Kakusan Koso; 2001 Apr; 46(5):621-8. PubMed ID: 11296359
    [No Abstract]   [Full Text] [Related]  

  • 33. Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function.
    Smith JP; Weller S; Johnson B; Nicotera J; Luther JM; Haas DW
    Antimicrob Agents Chemother; 2010 Mar; 54(3):1146-51. PubMed ID: 20038622
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cellular uptake mechanism of amino acid ester prodrugs in Caco-2/hPEPT1 cells overexpressing a human peptide transporter.
    Han HK; Oh DM; Amidon GL
    Pharm Res; 1998 Sep; 15(9):1382-6. PubMed ID: 9755889
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An investigation of the steady-state pharmacokinetics of oral valacyclovir in immunocompromised children.
    Nadal D; Leverger G; Sokal EM; Floret D; Perel Y; Leibundgut K; Weller S
    J Infect Dis; 2002 Oct; 186 Suppl 1():S123-30. PubMed ID: 12353197
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Case files of the Harvard medical toxicology fellowship: valacyclovir neurotoxicity and unintentional overdose.
    Huguenel C; Felton D; Bruccoleri R; Salhanick S
    J Med Toxicol; 2015 Mar; 11(1):132-6. PubMed ID: 25539699
    [No Abstract]   [Full Text] [Related]  

  • 37. Intra- and interindividual variabilities of valacyclovir oral bioavailability and effect of coadministration of an hPEPT1 inhibitor.
    Phan DD; Chin-Hong P; Lin ET; Anderle P; Sadee W; Guglielmo BJ
    Antimicrob Agents Chemother; 2003 Jul; 47(7):2351-3. PubMed ID: 12821497
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and bioequivalence study of valacyclovir hydrochloride capsules after single dose administration in healthy Chinese male volunteers.
    Lin H; Tian Y; Tian JX; Zhang ZJ; Mao GG
    Arzneimittelforschung; 2010; 60(3):162-7. PubMed ID: 20422949
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of ionization on the variable uptake of valacyclovir via the human intestinal peptide transporter (hPepT1) in CHO cells.
    Balimane P; Sinko P
    Biopharm Drug Dispos; 2000 Jul; 21(5):165-74. PubMed ID: 11180195
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Valacyclovir neurotoxicity in a patient with end-stage renal disease treated with continuous ambulatory peritoneal dialysis.
    Okada T; Nakao T; Matsumoto H; Nagaoka Y; Iwasawa H; Nanri K; Yamazaki T
    Clin Nephrol; 2002 Aug; 58(2):168-70. PubMed ID: 12227692
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.